CN101926999B - Hemostatic disinfectant and preparation method thereof - Google Patents
Hemostatic disinfectant and preparation method thereof Download PDFInfo
- Publication number
- CN101926999B CN101926999B CN2009100874279A CN200910087427A CN101926999B CN 101926999 B CN101926999 B CN 101926999B CN 2009100874279 A CN2009100874279 A CN 2009100874279A CN 200910087427 A CN200910087427 A CN 200910087427A CN 101926999 B CN101926999 B CN 101926999B
- Authority
- CN
- China
- Prior art keywords
- disinfectant
- hemostatic
- concentration
- defibrase
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a hemostatic disinfectant. The solution of the hemostatic disinfectant comprises 0.1 to 50 mu m/ml hemostatic biological enzyme, a disinfectant of which the concentration can achieve sterilization and disinfection effects and 1 to 100 mg/ml protein protective agent. The hemostatic disinfectant is more suitable for cleaning and disinfecting the wound surface of skin, a mucous membrane or a tissue in surgical operation, stopping bleeding for a traumatic wound and disinfecting the traumatic wound. The invention also provides a method for preparing the hemostatic disinfectant. The preparation method comprises the following step of: preparing the solution of the hemostatic disinfectant which comprises 0.1 to 50 mu m/ml hemostatic biological enzyme, the disinfectant of which the concentration can achieve the sterilization and disinfection effects and 1 to 100 mg/ml protein protective agent.
Description
Technical field
The present invention relates to a kind of disinfectant and preparation method thereof, relate more specifically to a kind of hemostatic disinfectant and preparation method thereof.
Background technology
Along with the global climate deterioration with environmental pollution of warming; Various microorganisms particularly kind and the procreation speed of invasive organism all in continuous rising; The human body that causes thus also rises rapidly with the sickness rate of animal various diseases thereupon, so that the use of disinfectant seems is particularly important.Disinfectant is mainly used in two broad aspect: the first is to the sterilization of body surfaces such as air ambient, installations and facilities, clothing utensil; It two is the sterilizations to organism surfaces such as skin, mucosa, wound and wound surface of medical aspect.The use of disinfectant should be selected different type and concentration according to different sterilization objects.Aspect medical; The most frequently used disinfectant of hospital has mercurochrome, gentian voiet, 75% ethanol, povidone iodine, iodine raised path between farm fields, hibitane etc. at present; Processing for surgical operation wound surface or traumatic wounds mainly is earlier with a large amount of sterile saline flushings; With disinfectant wipings such as povidone iodine, wrapping or sew up wound stop blooding and prevent pollution at last then.
Chinese medicine not only can be treated disease; Many Chinese medicines also have a stronger antibiosis and antiviral functions external; Has use value widely; But the research of Chinese medicine antiseptic but seldom, and disinfectant (particularly Chinese medicine antiseptic) is combined with the hemostasis enzyme, prepares a kind ofly to get final product the hemostatic disinfectant simultaneously at disinfectant and do not see also that at present report is arranged.
Summary of the invention
Deficiency to prior art exists the invention provides a kind of hemostatic disinfectant, through disinfectant is combined with the hemostasis enzyme, reaches anastalsis simultaneously at disinfectant, can be widely used in the sterilization and the hemostasis of surgical operation wound surface or traumatic wounds.The present invention also provides the method for preparing of this hemostatic disinfectant.
The present invention combines the disinfectant of debita spissitudo with the hemostasis enzyme, a kind of low toxic and side effects is provided and the disinfectant of hemostatic function is arranged.
In the present invention, add an amount of protein protective agent as the case may be.Disinfectant great majority of the prior art reach bactericidal effect through the tropina degeneration, if simply both are combined, disinfectant can be destroyed the enzyme of hemostasis enzyme and live, and reduce perhaps losing haemostatic effect.In order to address this problem, the present invention has added an amount of protein protective agent, guarantees the enzyme non-inactivation, plays haemostatic effect.
When hemostasis enzyme concentration is 0.1u/ml; It is longer to reach the required time of haemostatic effect; And when hemostasis enzyme concentration surpasses 50u/ml; Although external haemostatic effect is fine, the batroxobin of high concentration can disturb the balance with dissolution system of solidifying of blood after by tissue absorption, causes use cost to improve simultaneously.Therefore, consider that according to aspects such as bleeding stopping period length, wound surface size, amount of bleeding what and production costs the concentration of the enzyme that preferably stops blooding is 0.1～50u/ml, more preferably 1～20u/ml.
Disinfectant of the present invention can be chemosterilant, also can be Chinese medicine antiseptic.Said Chinese medicine antiseptic is plant extract or its main active with antibacterial and anti-inflammation functions.
The decontaminant concentration that is adopted among the present invention is different because of the kind of disinfectant, and those skilled in the art can confirm to reach the decontaminant concentration of disinfection effect according to the concrete disinfectant that is adopted.Therefore, among the present invention, the disinfectant of said debita spissitudo just is meant the decontaminant concentration that can reach disinfection effect.
That is, in the solution of said hemostatic disinfectant, the hemostasis enzyme that comprises concentration and be 0.1～50u/ml with have the disinfectant that can reach disinfection effect concentration.The solution preferred aqueous solutions of said hemostatic disinfectant.
For example, the concentration range of chemosterilant can be 0.01%～1% (w/v or v/v or w/w), and the concentration of Chinese medicine antiseptic can be 10 μ g/ml～500mg/ml.
For example, said chemosterilant should act on fast, effectively and to skin, mucosa is nontoxic has no stimulation, for example, can be benzalkonium bromide (bromogeramine), hibitane, povidone iodine etc., but be not limited thereto.Consider that this disinfectant is mainly used in skin mucosa, wound surface particularly, so locate preferred bland povidone iodine, povidone iodine concentration can be 0.05%～1.0% (w/v or v/v or w/w).
In the present invention; Chinese medicine antiseptic promptly is meant plant extract or its main active with antibacterial and anti-inflammation functions; Its should have the extract of antiinflammatory, sterilization functions and to skin, mucosa is nontoxic has no stimulation; For example, can be Sodium Houttuyfonate, Herba Houttuyniae extract, fresh garlic extract, Flos Lonicerae extract, Herba portulacae extract etc., but be not limited thereto.Consider the assay method and the cost problem of bactericidal effect, effective ingredient, preferred Sodium Houttuyfonate, concentration can be 50～400 μ g/ml.In the present invention, the Sodium Houttuyfonate in the Chinese medicine antiseptic is slightly soluble in water, in order to increase dissolubility, adds a spot of cosolvent during preparation, and for example glycerol, tween-80 etc. for example can add the glycerol of 0.2-5ml in per 100 ml water solution.
Said hemostasis enzyme can be thrombin, batroxobin or other enzyme at external enzyme with hemostatic function.Batroxobin can comprise Defibrase, batroxobin, reptilase etc., but is not limited thereto.The bleeding stopping period of Defibrase is short, and effect is good than other enzyme, considers the convenience and the cost problem of preparation, preferred here Defibrase, and concentration can be 0.1～50u/ml, preferred Defibrase concentration is .1～20u/ml.
Among the present invention, the enzyme in the disinfectant can be freeze-drying prods or solution, but for the biological activity that keeps enzyme and the convenience of transportation and storage, preferably dried frozen aquatic products faces the time spent preparation.
Generally all contain a certain amount of protein protective agent in lyophilized powder or the aqueous solution hemostasis biological enzyme formulation.For example, in batroxobin solution, comprise the protein protective agent of 0.1～50mg/ml usually; For the batroxobin freeze-drying prods, comprise the protein protective agent of 0.1～50mg/ml in the solution before the lyophilizing usually, the ratio of batroxobin and protein protective agent is preferably 10u/mg.Therefore, to enzyme influence size alive, can suitably add a certain amount of protein protective agent among the present invention according to disinfectant, the concentration range of protein protective agent in hemostatic disinfectant solution of the present invention is preferably 1～100mg/ml.Protein protective agent described herein is brain albumen, arginine, lysine, sucrose, mannitol etc., but is not limited thereto.Add arginine, enzyme is lived and is not reduced basically, and taking cost into account more suitable, so the preferred arginine of protective agent, its preferred concentration is 5～15mg/ml, most preferably 10mg/ml.
Thrombin is the natural component in the body blood coagulation system; Be a kind of multifunctional protein enzyme that is created on the injury region vascular endothelial cell, it is to participate in the key enzyme in each link reaction in the coagulation process, and finished product is white amorphous powder; Water-soluble, be insoluble to organic solvent.
The batroxobin great majority are extracted by snake venom; Snake venom thrombin-like enzyme is a kind of serine protease with arginine esterase and lactamase activity; Can in coagulation process, play a significant role, because of its 26S Proteasome Structure and Function similar with human prothrombin, so claim " batroxobin ".Snake venom thrombin-like enzyme has similar pharmacological action with thrombin; Be that they have arginine ester enzymatic activity direct hydrolysis Fibrinogen α chain or β chain; Discharge fibrinopeptide A or fibrinopeptide B, and aggregate into fibrin polymer, promote the platelet aggregation of blood vessel breakage; Quicken the formation of platelet tampon, play anastalsis.Difference is that the blood coagulation activity of batroxobin is not suppressed by inhibitor such as heparin, Antithrombin III, hirudin, soybean trypsin.
According to a further aspect in the invention; The invention provides the method for preparing of said hemostatic disinfectant; This method for preparing comprises the steps: to prepare the solution of hemostatic disinfectant; Wherein, comprise 0.1～50u/ml the hemostasis enzyme, to have the disinfectant and the concentration that can reach disinfection effect concentration be the protein protective agent of 1～100mg/ml.Said preparation preferably faces the time spent preparation, and the hemostasis enzyme and the disinfectant that are about to place are separately mixed each other, process hemostatic disinfectant; If hemostasis enzyme and disinfectant are solid, then can be mixed in proportion in advance, with before being dissolved in water.Owing to comprised a certain amount of protein protective agent usually in the hemostasis enzyme product, therefore, to enzyme influence size alive, the present invention can select not add protein protective agent, also can suitably add a certain amount of protein protective agent according to disinfectant.
In order to understand essence of the present invention better,, specify but do not limit the present invention below through to the description of preferred embodiments among the present invention.
The specific embodiment
The used test material of the present invention if no special instructions, is the commercially available prod.Defibrase is already produced the preparation of listing or the commercially available prod of other manufacturer production for the match crude drug.
The preparation of hemostatic disinfectant
The Defibrase that in the following example, uses itself contains the arginine protective agent of 1mg/10U.
Embodiment 1 Sodium Houttuyfonate 5mg, glycerol 0.5ml add water 90ml and are dissolved as the A agent; Defibrase 100 units (itself containing the 10mg arginine) and arginine 990mg are the B agent.Face with preceding A, B are mixed, add water and be settled to the 100ml mixing, be the antiseptic solution that contains Defibrase 1u/ml, Sodium Houttuyfonate 50 μ g/ml.
Embodiment 2 Sodium Houttuyfonate 10mg, glycerol 1ml add water 90ml and are dissolved as the A agent; Defibrase 5000 units (itself containing the 500mg arginine) and arginine 500mg are the B agent.Face with preceding A, B are mixed, add water and be settled to the 100ml mixing, be the antiseptic solution that contains Defibrase 50u/ml, Sodium Houttuyfonate 100 μ g/ml.
Embodiment 3 Sodium Houttuyfonate 15mg, glycerol 1.5ml add water 90ml and are dissolved as the A agent; Defibrase 2000 units (itself containing the 200mg arginine) and arginine 800mg are the B agent.Face with preceding A, B are mixed, add water and be settled to the 100ml mixing, be the antiseptic solution that contains Defibrase 20u/ml, Sodium Houttuyfonate 150 μ g/ml.
Embodiment 4 faces with the preceding Sodium Houttuyfonate 15mg that gets respectively, and glycerol 2ml and Defibrase 2000 units (itself containing the 200mg arginine) and arginine 800mg add water and be settled to the 100ml mixing.Be mixed with the antiseptic solution that contains Defibrase 20u/ml, Sodium Houttuyfonate 150 μ g/ml.
Embodiment 5 Sodium Houttuyfonate 40mg, glycerol 4ml add water 90ml and are dissolved as the A agent; Defibrase 100 units (itself containing arginine 10mg) and arginine 990mg are the B agent.Face with preceding A, B are mixed, add water and be settled to the 100ml mixing.Process the antiseptic solution that contains Defibrase 1u/ml, Sodium Houttuyfonate 400 μ g/ml.
Embodiment 6 Sodium Houttuyfonate 40mg, glycerol 4ml adds water 90ml and is dissolved as the A agent; Adding Defibrase 5000 units (itself containing the 500mg arginine) and arginine 500mg is the B agent.Face with preceding A, B are mixed, add water, be settled to the 100ml mixing.Be mixed with the antiseptic solution that contains Defibrase 50u/ml, Sodium Houttuyfonate 400 μ g/ml.
Embodiment 7 Herba Houttuyniae 5Kg clean, and dehydrate is pulverized; According to solid-to-liquid ratio is to add entry at 1: 15, and 90 ℃ of water-bath lixiviate 3h filter; Add 80 ℃ of extractions of ethyl acetate 2h in the filtrating; Remove polysaccharide with 95% ethanol, filter; The filtrating vacuum concentration is dry.Get dry extract 100mg, add Defibrase 5000 units (itself containing arginine 500mg) and arginine 500mg, add water and be settled to the 100ml mixing.Be mixed with the disinfectant solution that contains Defibrase 50u/ml, Herba Houttuyniae extract 1mg/ml.
Embodiment 8 Herba Houttuyniae 5Kg clean, and dehydrate is pulverized; According to solid-to-liquid ratio is to add entry at 1: 20, and 90 ℃ of water-bath lixiviate 3h filter; Add 80 ℃ of extractions of ethyl acetate 2h in the filtrating; Remove polysaccharide with 95% ethanol, filter; The filtrating vacuum concentration is dry.Get the 500mg dry extract, add Defibrase 100 units (itself containing arginine 10mg) and arginine 990mg, add water and be settled to the 100ml mixing.Be mixed with the disinfectant solution that contains Defibrase 1u/ml, Herba Houttuyniae extract 5mg/ml.
Embodiment 9 Herba Houttuyniae 5Kg clean, and dehydrate is pulverized; According to solid-to-liquid ratio is to add entry at 1: 20, and 90 ℃ of water-bath lixiviate 2h filter; Add ethyl acetate in the filtrating, 80 ℃ of extraction 2h remove polysaccharide with 95% ethanol, filter; The filtrating vacuum concentration is dry.Get the 5g dry extract, add Defibrase 2000 units (itself containing arginase 12 00mg) and arginine 800mg mixing, add water and be settled to the 100ml mixing.Be mixed with the disinfectant solution that contains Defibrase 20u/ml, Herba Houttuyniae extract 50mg/ml.
Embodiment 10 new fresh Herba Portulacae 1kg clean, and after adding water 1000ml very hot oven and frying in shallow oil out, reuse slow fire boiling 10min filters, the about 800ml of filter liquor.Filter liquor is concentrated into about 50ml, adds Defibrase 1000u (itself containing arginine 100mg) and arginine 400mg, add water and be settled to the 100ml mixing.Be mixed with the Herba Portulacae antiseptic solution that contains Defibrase 10u/ml.
Embodiment 11 takes by weighing exsiccant Honeysuckle Flower 1Kg, and decocte with water 3 times merges decoction liquor; Filter, filtrating cold preservation is spent the night; The centrifugal 25min of 3500r/min; Get supernatant in 60 ℃ of concentrating under reduced pressure, in concentrated solution, add suitable quantity of water, magnetic agitation 30min, refrigerator overnight; Remove by filter insoluble impurities; Filtrating adjust pH to 5～7.; Last macroporous resin adsorption post.Collect eluent, be concentrated into about 50ml, add Defibrase 1000u (itself containing arginine 100mg) and arginine 400mg, add water and be settled to the 100ml mixing.Be mixed with the Flos Lonicerae disinfectant solution that contains Defibrase 10u/ml.
Embodiment 12 Defibrase 2000u (including arginase 12 00mg) and arginine 800mg, the bromo geramine solution with 0.05%～1.0% is settled to the 100ml mixing, is mixed with the bromo geramine antiseptic solution that contains Defibrase 20u/ml.Also can its independent packing be faced and used preceding preparation.
The Disinfection Effect of hemostatic disinfectant
The sample that embodiment 13 the gets embodiment 3 preparation effect assessment that carries out disinfection, specific as follows:
1, the preparation of bacteria suspension and bacterium sheet
Depletion Staphylococcus aureus (ATCC6538), Pseudomonas aeruginosa (ATCC15442), the fresh slant culture of Candida albicans (ATCC10231) 18～24h; 0.03mol/LPBS with containing the 10g/L peptone washes and is diluted to desired concn; Mixing is processed bacteria suspension.Getting the above-mentioned bacteria suspension of 20 μ l dyes in the white plain sheet of aseptic defat and (on the 10mm * 10mm), processes the bacterium sheet.
2, nertralizer is selected test
Test according to the carrier quantitation sterilisation program with staphylococcus aureus and Candida albicans.6 groups of parallel testings are carried out in test.The result judges by the execution of " disinfection technology standard " specified standard, test repetition 3 times.The result is following:
Table 1 nertralizer qualification test result
Nertralizer selects result of the test to prove, uses the PBS solution that contains 10g/L lecithin+10g/L Tween 80 as nertralizer standard up to specification.
3, carrier quantitative germicidal test
The disinfectant of preparation variable concentrations is sub-packed in the plate according to the consumption of 1 bacterium sheet 5ml disinfectant, puts in 20 ± 2 ℃ of water-baths to constant temperature.Add the test organisms sheet respectively, the effect stipulated time, neutralization 10min, the antibacterial on the rapping eluting bacterium sheet, mixing are equipped with in the test tube of 5ml nertralizer in the immigration of bacterium sheet.Get aforesaid liquid or its diluent 0.5ml is inoculated in plate, and pour into the required agar culture medium of each bacterium, cultivate, do the viable bacteria numeration, calculate killing rate by each bacterium condition of culture.The test repetition is averaged for 3 times.The result sees table 2.
Table 2 disinfectant is to the killing effect of antibacterial
4, stability test result
With packaged disinfectant, to put in 54 ℃ of calorstats behind the 14d, the disinfectant of getting before and after storing is carried out BA, with the disinfectant effect 5min of 110mg/L, the killing rate of Candida albicans on the cloth sheet is dropped to more than 98.87% by storage preceding 98.93%.With store before compare, its bactericidal effect no significant difference is explained its stable performance, meets demand of technical standard.
The hemostatic disinfectant that employing is prepared by the foregoing description 1～12, according to the method for embodiment 13 effect test that carries out disinfection, the result shows all have preferable bactericidal effect.
The haemostatic effect of hemostatic disinfectant
The sample that embodiment 14 gets embodiment 3 preparations carries out the haemostatic effect evaluation, and is specific as follows:
Trial test: selecting body weight for use is the female new zealand white rabbit of 1.5 ± 0.25Kg, and the method for list of references is made Hepar Leporis seu Oryctolagi wound hemorrhage model, adopts 1.5% pentobarbital sodium, and dosage is anaesthetized for the 30mg/kg intravenously administrable.After anaesthetizing successfully, successively open abdomen, expose liver,, cause 1cm at 2cm place cut-out hepatic tissue on liver lobus sinister lower edge
2Hemorrhage wound surface is used hemostatic disinfectant and gauze and is stopped blooding, and observes and record bleeding stopping period and amount of bleeding etc.After confirming haemostatic effect, trial test finishes, the layer-by-layer suture wound.
EXPERIMENTAL DESIGN and grouping: choose 24 new zealand white rabbits, be divided into 4 groups at random, 6 every group.
Observation index:
1) bleeding time is sprayed the hemostatic disinfectant 5ml of variable concentrations respectively on onesize hemorrhage wound surface, adds a cover gauze, pressurizes on gauze with the 50g counterweight.Every separated 30s observes 1 hemorrhage situation to stopped bleeding, the record bleeding time.
2) amount of bleeding puts it into the weighing botle sealing and weighs with precise electronic balance weigh in advance gauze and empty weighing botle after the hemostasis, calculates blood volume.
Result of the test: table 3 is the result show, on hemorrhage wound surface, sprays the hemostatic disinfectant Defibrase of variable concentrations, and its bleeding stopping period and amount of bleeding all have apparent difference with matched group, and along with Defibrase concentration is dose-effect relationship.Since the 20u/ml group has had very significantly haemostatic effect, consider that from safety, practicality and economy the Defibrase concentration of preferred 20u/ml is comparatively suitable.
The bleeding stopping period and the amount of bleeding of table 3 variable concentrations disinfectant
Compare with matched group,
*P＜0.05;
*P＜0.01
The hemostatic disinfectant that adopts the foregoing description to prepare carries out the haemostatic effect test according to the method for embodiment 14, and the result shows all have preferable haemostatic effect.
The stability of hemostatic disinfectant
The sample that embodiment 15 gets embodiment 3 preparations carries out stable accelerated test, gets packaged disinfectant and puts 37 ℃ of calorstats interior 3 months, measures the content of Sodium Houttuyfonate and the activity of Defibrase.Mensuration result shows that the houttuynine sodium bisulfite sodium content is 98.3% before the accelerated test, and the activity of Defibrase is 97.7% before the accelerated test, has no significant change.
The hemostatic disinfectant that adopts the foregoing description to prepare carries out stable accelerated test according to the method for embodiment 15, and the result shows that hemostatic disinfectant of the present invention is stable.
More than the description of preferred embodiments of the present invention is not limited the present invention, those skilled in the art can make multiple change or combination according to the present invention, only otherwise break away from spirit of the present invention, all should belong to the scope of accompanying claims of the present invention.
Claims (12)
1. hemostatic disinfectant; It is characterized in that; In said hemostatic disinfectant solution, comprise hemostasis enzyme, 0.01～1% disinfectant and the protein protective agent of 1～100mg/ml of the local quick-acting haemostatic powder effect of having of 0.1～50u/ml with the concentration that can reach disinfection effect.
2. hemostatic disinfectant according to claim 1 is characterized in that, said disinfectant composition is a chemosterilant, and the concentration of said chemosterilant is 0.01%～1%.
3. hemostatic disinfectant according to claim 1 is characterized in that, said disinfectant composition is a Chinese medicine antiseptic, and the concentration of said Chinese medicine antiseptic is 10 μ g/ml～500mg/ml.
4. hemostatic disinfectant according to claim 1 is characterized in that, said hemostasis enzyme is to be selected from one or more of batroxobin and thrombin.
5. hemostatic disinfectant according to claim 1 and 2 is characterized in that, said chemosterilant is to be selected from one or more of benzalkonium bromide, hibitane, povidone iodine.
6. according to claim 1,2, one of 5 described hemostatic disinfectants, it is characterized in that said chemosterilant is a povidone iodine.
7. according to claim 1 or 3 described hemostatic disinfectants, it is characterized in that said Chinese medicine antiseptic is selected from one or more of Sodium Houttuyfonate, Herba Houttuyniae extract, fresh garlic extract, Flos Lonicerae extract and Herba portulacae extract.
8. according to claim 1 or 7 described hemostatic disinfectants, it is characterized in that said Chinese medicine antiseptic is Sodium Houttuyfonate, Herba Houttuyniae extract or Flos Lonicerae extract.
9. according to claim 1 or 4 described hemostatic disinfectants, it is characterized in that described batroxobin is be selected from Defibrase, batroxobin, reptilase at least a.
10. according to claim 1,4, one of 9 described hemostatic disinfectants, it is characterized in that described batroxobin is a Defibrase.
11. hemostatic disinfectant according to claim 1 is characterized in that, said protein protective agent is to be selected from one or more of brain albumen, arginine, lysine, sucrose and mannitol.
12. method for preparing the described hemostatic disinfectant of claim 1～11; It is characterized in that; Said method for preparing comprises the steps: to prepare said hemostatic disinfectant solution; Wherein, the hemostasis enzyme, 0.01～1% disinfectant and the protein protective agent of 1～100mg/ml that comprise the local quick-acting haemostatic powder effect of having of 0.1～50u/ml with the concentration that can reach disinfection effect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100874279A CN101926999B (en) | 2009-06-22 | 2009-06-22 | Hemostatic disinfectant and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100874279A CN101926999B (en) | 2009-06-22 | 2009-06-22 | Hemostatic disinfectant and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101926999A CN101926999A (en) | 2010-12-29 |
| CN101926999B true CN101926999B (en) | 2012-02-29 |
Family
ID=43366596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100874279A Active CN101926999B (en) | 2009-06-22 | 2009-06-22 | Hemostatic disinfectant and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101926999B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108245669A (en) * | 2018-02-06 | 2018-07-06 | 昆明龙津药业股份有限公司 | The Defibrase injection and preparation method of a kind of stabilization |
| CN109010807A (en) * | 2018-09-30 | 2018-12-18 | 刘家鹤 | A kind of disinfectant with hemostatic function |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103394012A (en) * | 2013-08-16 | 2013-11-20 | 李蓓 | Medical skin disinfection liquid |
| CN104435606A (en) * | 2014-11-28 | 2015-03-25 | 成都顺发消洗科技有限公司 | Chinese herbal medicine skin disinfectant |
| CN104434667A (en) * | 2014-11-28 | 2015-03-25 | 成都顺发消洗科技有限公司 | Chinese herbal medicine skin disinfectant wet wipe |
| CN107841526A (en) * | 2017-11-16 | 2018-03-27 | 北华大学 | A kind of malic dehydrogenase diagnostic kit |
| CN112138068A (en) * | 2020-09-14 | 2020-12-29 | 可帮(天津)高新技术有限公司 | Skin-moistening type disinfectant and production method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060959A (en) * | 1990-10-28 | 1992-05-13 | 石光生 | Aerosols for protective film of medicine " Hemostatic-Yantongting " |
| CN1181239A (en) * | 1996-10-29 | 1998-05-13 | 胥江 | Method for preparing film forming sterilizing agent |
| CN1727002A (en) * | 2004-07-26 | 2006-02-01 | 周长海 | Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination |
| CN101214374A (en) * | 2007-01-05 | 2008-07-09 | 兆科药业（合肥）有限公司 | Preparations with procoagulant and hemostasis function |
-
2009
- 2009-06-22 CN CN2009100874279A patent/CN101926999B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060959A (en) * | 1990-10-28 | 1992-05-13 | 石光生 | Aerosols for protective film of medicine " Hemostatic-Yantongting " |
| CN1181239A (en) * | 1996-10-29 | 1998-05-13 | 胥江 | Method for preparing film forming sterilizing agent |
| CN1727002A (en) * | 2004-07-26 | 2006-02-01 | 周长海 | Compound bioogic component and pharmaceutical preparation possessing function for accelerating hemoglutination |
| CN101214374A (en) * | 2007-01-05 | 2008-07-09 | 兆科药业（合肥）有限公司 | Preparations with procoagulant and hemostasis function |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108245669A (en) * | 2018-02-06 | 2018-07-06 | 昆明龙津药业股份有限公司 | The Defibrase injection and preparation method of a kind of stabilization |
| CN109010807A (en) * | 2018-09-30 | 2018-12-18 | 刘家鹤 | A kind of disinfectant with hemostatic function |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101926999A (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101926999B (en) | Hemostatic disinfectant and preparation method thereof | |
| AU2016214119B2 (en) | Antimicrobial fibers and compositions | |
| EP1905443B1 (en) | Liquid comprising trehalose for use in preventing tissue adhesion | |
| US5945446A (en) | Process for preparing synthetic soil-extract materials and medicaments based thereon | |
| Eberlein et al. | Clinical use of polihexanide on acute and chronic wounds for antisepsis and decontamination | |
| CN109316536A (en) | A kind of skin mucosa disinfecting agent and preparation method thereof | |
| AU2015352171A1 (en) | Prevention and treatment of microbial infections | |
| JP3037355B2 (en) | Method for producing therapeutic agent for patients with thrombosis | |
| US20200323963A1 (en) | Antimicrobial fibers and compositions | |
| Vachhrajani et al. | Science of wound healing and dressing materials | |
| CN108888758A (en) | Collagen gynaecologic washing lotion and preparation method thereof | |
| US20110086106A1 (en) | Method of producing a dry earthworm powder | |
| CN109331219A (en) | A kind of chitosan liquid dressing | |
| CN103263434A (en) | Anti-adhesion liquor for wound washing and surgery and preparation method and application of anti-adhesion liquor | |
| Hossain et al. | In-Vitro Thrombolytic and Anti-inflammatory Activity of Swertia Chirata Ethanolic Extract. | |
| JP5596561B2 (en) | Pharmaceutical compositions, dressings and methods for treating skin lesions, intermediate compositions and processes for preparing the dressings, and use of cerium salts in combination with a collagen matrix | |
| JP2009522254A (en) | Anticoagulant and composition for preventing thrombus containing polyγ-glutamic acid as active ingredient | |
| KR20020008824A (en) | Acidic solution of sparingly-soluble group IIA complexes | |
| CN1517126B (en) | Drug compastion with thrombolysis, anti-inflammatory and cell protective function | |
| CN104666317B (en) | A kind of neonatal umbilical cord antibacterial anti-inflammatory liquid and its preparation method and application | |
| CN110507851A (en) | A kind of absorbable bone wax and preparation method thereof | |
| CN109200326A (en) | Dressing and bandage for wound healing | |
| CN106822986B (en) | A kind of preparation method of the porous ball hemostatic material of chitosan-agar oligosaccharide | |
| WO2017060821A1 (en) | Hemostatic composition | |
| CN105012992B (en) | A kind of medical bio vagina hydrogel functional dressing and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 100176 No. 8 prosperous street, Beijing economic and Technological Development Zone, Beijing Applicant after: Beijing Science Sun Pharmaceutical Co., Ltd. Address before: 100176 No. 8 prosperous street, Beijing economic and Technological Development Zone, Beijing Applicant before: Beijing Saisheng Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |